Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
31200358
2.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108
3.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29.

PMID:
30694529
4.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
5.

Risk-adapted therapy for advanced-stage Hodgkin lymphoma.

Spinner MA, Advani RH.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):200-206. doi: 10.1182/asheducation-2018.1.200. Review.

PMID:
30504311
6.

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Spinner MA, Varma G, Advani RH.

Br J Haematol. 2019 Jan;184(1):17-29. doi: 10.1111/bjh.15616. Epub 2018 Nov 28. Review.

PMID:
30485408
7.

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:626-636. doi: 10.1200/EDBK_200679. Review.

PMID:
30231319
8.

Novel Approaches in Waldenström Macroglobulinemia.

Spinner MA, Varma G, Advani RH.

Hematol Oncol Clin North Am. 2018 Oct;32(5):875-890. doi: 10.1016/j.hoc.2018.05.014. Epub 2018 Jul 19. Review.

PMID:
30190025
9.

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA.

J Clin Oncol. 2018 Oct 20;36(30):3015-3022. doi: 10.1200/JCO.2018.79.0139. Epub 2018 Sep 4.

PMID:
30179569
10.

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.

PMID:
30125215
11.

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS.

Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071. No abstract available.

12.

Advances in the management of primary mediastinal large B-cell lymphoma.

Advani RH.

Clin Adv Hematol Oncol. 2018 Jan;16(1):33-34. No abstract available.

PMID:
29741502
13.

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.

Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH; T cell Project Network.

Br J Haematol. 2018 Jun;181(6):760-769. doi: 10.1111/bjh.15258. Epub 2018 Apr 19.

14.

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.

Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M; International T-cell Project Network.

Haematologica. 2018 Jul;103(7):1191-1197. doi: 10.3324/haematol.2017.186577. Epub 2018 Mar 29.

15.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.

J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.

PMID:
29523663
16.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR.

Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.

17.

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Swinnen LJ, O'Neill A, Imus PH, Gujar S, Schiff D, Kleinberg LR, Advani RH, Dunbar EM, Moore D, Grossman SA.

Oncotarget. 2017 Nov 6;9(1):766-773. doi: 10.18632/oncotarget.22332. eCollection 2018 Jan 2.

18.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH.

Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11.

19.

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.

Kunder CA, Roncador G, Advani RH, Gualco G, Bacchi CE, Sabile JM, Lossos IS, Nie K, Tibshirani RJ, Green MR, Alizadeh AA, Natkunam Y.

Am J Clin Pathol. 2017 Nov 20;148(6):465-476. doi: 10.1093/ajcp/aqx099.

20.

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation.

Lynch RC, Advani RH.

Case Rep Oncol. 2017 Sep 12;10(3):813-818. doi: 10.1159/000480292. eCollection 2017 Sep-Dec.

21.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.

Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.

22.

Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Lynch RC, Gratzinger D, Advani RH.

Curr Treat Options Oncol. 2017 Oct;18(10):60. doi: 10.1007/s11864-017-0499-4. No abstract available.

PMID:
28861885
23.

Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center.

Porter JB, Rosenthal EL, Winget M, Smith AS, Seshadri SB, Vetteth Y, Kiamanesh EF, Badwe A, Advani RH, Buyyounouski MK, Coutre S, Dirbas F, Divi V, Dorigo O, Ganjoo KN, Johnston LJ, Recht LD, Shrager JB, Skinner EC, Swetter SM, Visser BC, Blayney DW.

J Oncol Pract. 2017 Aug;13(8):e673-e682. doi: 10.1200/JOP.2017.021139. Epub 2017 Jul 20.

24.

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Lynch RC, Gratzinger D, Advani RH.

Curr Treat Options Oncol. 2017 Jul;18(7):45. doi: 10.1007/s11864-017-0483-z. Review. Erratum in: Curr Treat Options Oncol. 2017 Oct;18(10 ):60.

PMID:
28670664
25.

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM.

Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.

26.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H.

J Natl Compr Canc Netw. 2017 May;15(5):608-638.

PMID:
28476741
27.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID:
28275031
28.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
29.

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.

Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS.

Oncology (Williston Park). 2016 Dec 15;30(12):1099-103, 1106-8. Review.

30.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

31.

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.

Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED.

Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20.

PMID:
27868471
32.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA.

Sci Transl Med. 2016 Nov 9;8(364):364ra155.

33.

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ.

Cancer Immunol Res. 2016 Nov;4(11):910-916. Epub 2016 Oct 13.

34.

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS.

Leukemia. 2017 Feb;31(2):517-519. doi: 10.1038/leu.2016.305. Epub 2016 Oct 26. No abstract available.

35.

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh HJ, Jones S, Chu YW, Cheson BD.

Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. doi: 10.1158/1078-0432.CCR-16-0772. Epub 2016 Sep 6.

36.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.

J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.

PMID:
27587620
37.

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, Advani RH.

Br J Haematol. 2018 Jan;180(1):164-166. doi: 10.1111/bjh.14302. Epub 2016 Aug 18. No abstract available.

PMID:
27539794
38.

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.

Varma G, Johnson TP, Advani RH.

Clin Adv Hematol Oncol. 2016 Jul;14(7):543-54. Review. Erratum in: Clin Adv Hematol Oncol. 2016 Sep;14(9):728.

PMID:
27379948
39.

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.

Lynch RC, Advani RH.

Am Soc Clin Oncol Educ Book. 2016;35:e376-85. doi: 10.14694/EDBK_159036. Review.

40.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print] No abstract available.

PMID:
27081879
41.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print] No abstract available.

PMID:
27081876
42.

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA.

J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.

43.

Diffuse Large B-Cell Lymphoma Version 1.2016.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2016 Feb;14(2):196-231.

PMID:
26850490
44.

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM.

Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.

45.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH.

Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7.

46.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

47.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

48.

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.

Iberri DJ, Hoppe RT, Advani RH.

Curr Treat Options Oncol. 2015 Sep;16(9):45. doi: 10.1007/s11864-015-0360-6. Review.

PMID:
26187795
49.

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.

Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, Hoppe RT.

Leuk Lymphoma. 2016;57(3):604-8. doi: 10.3109/10428194.2015.1067700. Epub 2015 Aug 28.

PMID:
26159046
50.

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.

Advani RH, Hoppe RT.

Hematol Oncol. 2015 Jun;33 Suppl 1:90-5. doi: 10.1002/hon.2226. Review. No abstract available.

PMID:
26062064

Supplemental Content

Loading ...
Support Center